An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.

J Immunother Cancer · 2018 · PMC5905120 · PMID 29665849

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The peptide caused a highly significant extension of survival of mice with implanted ovarian cancer cells with a favorable toxicity and non-antigenic profile.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.